32 results about "Cardiac Progenitor Cell" patented technology

The present invention provides a novel method to isolate and expand pure progenitor / stem cells from a primary tissue explant, which produces a population enriched in multipotent functional progenitor / stem cells free of contaminating fibroblasts and other cell types. Cardiac progenitor / stem cells isolated by this method maintain their self-renewal and clonogenic character in vitro and differentiate into normal cells in myocardium, including cardiomyocytes, endothelial cells, and smooth muscle cells, after transplantation into ischemic hearts. The present invention also includes substantially pure populations of multipotent progenitor / stem cells, e.g., cardiac progenitor / stem cells, and their use to treat and prevent diseases and injuries, including those resulting from myocardial infarction.

The present invention provides methods for isolating human cardiac ventricular progenitor cells (HVPs), wherein cultures of day 5-7 cardiac progenitor cells are negatively selected for one or more first markers expressed on human pluripotent stem cells, such as TRA-1-60, to thereby isolate HVPs. The methods can further include positive selection for expression of a second marker selected from the group consisting of JAG1, FZD4, LIFR, FGFR3 and TNFSF9. Large populations, including clonal populations, of isolated HVPs that are first marker negative / second marker positive are also provided. Methods of in vivo use of the HVPs for cardiac repair or to improve cardiac function are also provided. Methods of using the HVPs for cardiac toxicity screening of test compounds are also provided.

An in vitro human cardiac multi potent or unipotent cell that has the ability to proliferate; may be maintained in standard cardiac stem cell media; can differentiate to a progenitor, precursor, or somatic cell; has the characteristics of a cardiac stem cell, a cardiac precursor cell, or a cardiac progenitor cell; does not exhibit uncontrolled growth, teratoma formation, or tumor formation in vivo; expresses one or more markers of a multipotent, unipotent or somatic cell not characteristic of a cardiac stem cell, a cardiac precursor cell, or a cardiac progenitor cell; and is derived from the reprogramming of a somatic cell, a progenitor cell or a stem cell that exhibits at least a transient increase in intracellular levels of at least one reprogramming agent; wherein the cell comprises at least one transiently expressed polypeptide or an expression vector.

Provided are a method for manufacturing a three-dimensional structure for cardiac muscular tissue regeneration, and a three-dimensional structure for cardiac muscular tissue regeneration, the method comprising the steps of: forming a three-dimensional structure by printing and crosslinking with a first bioprinting composition and a second bioprinting composition so as to alternately arrange a first bioprinted layer and a second bioprinted layer, wherein the first bioprinting composition contains cardiac progenitor cells and a tissue engineering structure formation solution containing decellularized extracellular matrix and a crosslinking agent, and the second bioprinting composition contains a tissue engineering structure formation solution, mesenchymal stem cells, and a vascular endothelial growth factor; and obtaining a crosslinked-gelled three-dimensional structure by performing thermal gelation on the crosslinked three-dimensional structure. The manufacturing method according to the present invention can uniformly position cardiac progenitor cells in the structure and maintain the viability of cells for a long time by implementing a blood vessel network composed of vascular cells in the structure, thereby remarkably improving the efficiency of cellular delivery into the myocardium.

The present invention provides a method for deriving a cardiac precursor cell or myocardial cell from a fibroblast. Provided is a method for producing a cardiac precursor cell that comprises introducing one myocardial reprogramming factor into a fibroblast, or a method for producing a myocardial cell that comprises introducing three myocardial reprogramming factors into a fibroblast.

The invention provides a kit for culturing cardiac progenitor cells. A plurality of reagent bottles are arranged in the kit and contain a culture solution I, a culture solution II, a growth factor I, a growth factor II, a growth factor III, a growth factor IV, a digestive solution, a cleaning solution, a cryopreservation solution and cell seeds respectively. By the adoption of the kit, culture, amplification and cryopreservation of cardiac progenitor cells can be achieved, the problems that the culture survival rate of cardiac progenitor cells is low, culture efficiency is low, inter-batch difference is large, and cryopreservation reactivation rate is not ideal are solved, cardiac progenitor cells can be amplified in an ideal nutrient balance state without differentiation, and rich sources are provided for further experimental study and medical treatment using cardiac progenitor cells. The kit is quite suitable for cardiac progenitor cell culture.

Provided are a composition for cell transplant and a method for cell transplant that allow myocytes and / or cardiac progenitor cells to be suitably maintained in myocardial tissue and allow the survival and proliferation of transplanted cells to be improved. This composition for cell transplant comprises cells and an aqueous solution of a protein (A), and is characterized in that: the cells are myocardial cells and / or cardiac progenitor cells; protein (A) has a hydrophobicity of 0.2-1.2; the protein (A) has a polypeptide chain (Y) and / or a polypeptide chain (Y'); the total number of polypeptidechains (Y) and polypeptide chains (Y') in the protein (A) is 1-100; the polypeptide chain (Y) is an amino acid sequence (X) repeated 2-100 times, the amino acid sequence being any one of a VPGVG sequence (1) which is an amino acid sequence represented by SEQ ID NO:1, a GVGVP sequence (2) which is an amino acid sequence represented by SEQ ID NO:2, a GPP sequence, a GAP sequence, and a GAHGPAGPK sequence (3), which is an amino acid sequence represented by SEQ ID NO:3; the polypeptide chain (Y') is the polypeptide chain (Y) where 0.1-5% of the amino acid residues thereof are substituted with lysine residues and / or arginine residues; and the total number of the lysine residues and arginine residues is 1-100.